

Special Issue

Biomarkers and Personalized Therapies in Pancreatic Cancer

Message from the Guest Editor

Pancreatic cancer is the most lethal of all solid malignancies, with a significant rise in deaths predicted by 2020. Currently, standard-of-care chemotherapeutics remain the best treatment option for patients. In this Special Issue, emerging opportunities to personalise a patient's treatment journey will be discussed. These include new strategies to detect the cancer and monitor a patient's response by a blood test, our evolving understanding of molecular profiles and tumour sub-types, a new understanding of the complex role the tumour microenvironment plays in treatment responses, selection of appropriate patients for targeted therapies, and opportunities to better segregate patients in design clinical trials.

Guest Editor

Dr. Tracy Putoczki

Personalized Oncology Division, The Walter and Eliza Hall Institute of Medical Research

Deadline for manuscript submissions

closed (31 October 2019)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/21820

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).